Carlos Gallardo

Statistics

Publications

Citations

2.9K

H-Index

Active since

2020

Affiliations

University of California, San Francisco(Current)

Fundación Arturo López Pérez

Hospital Kuala Lumpur

Seoul National University Hospital

Peter MacCallum Cancer Centre

Carlos Gallardo is an author at University of California, San Francisco specializing in triple-negative breast cancer therapy, chemotherapy, and breast cancer chemotherapy.

Publications per year

2020–2022

Publications

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés, Hope S. Rugo, David W. Cescon et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Hope S. Rugo, Peter Schmid, David W. Cescon et al. · Cancer Research · 2021 · 26 citations

Medicine, Oncology, Pharmacotherapy +17

1–3 of 3